SAN FRANCISCO – Full results from the HPS2-THRIVE study of Merck & Co. Inc.’s Tredaptive have heightened scrutiny about outcomes studies for cardiovascular drugs and may lead to changes in the way these studies are designed.
The more than 25,000-patient trial failed to show a significant improvement in cardiovascular outcomes with treatment with Merck’s combination of extended-release niacin and laropiprant, an anti-flushing compound intended to mitigate a common side effect of niacin. Announcing top-line results in December, Merck had said that it was dropping U.S
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?